Maintaining Function With Flexible Treatment Intervals Up To Q16 With Eylea

Dr. Javier Zarranz-Ventura discusses maintaining visual acuity with flexible treatment intervals for retinal conditions using an individualised treat-and-extend regimen. He highlights studies demonstrating the effectiveness of proactive interval management, with many patients achieving extended injection intervals (Q12 or Q16 weeks) while maintaining good visual outcomes. Key findings include 60% of patients reaching Q12 and 40% achieving Q16. He emphasises individualised care, where patients requiring frequent treatments initially can later transition to extended intervals. Dr. Ventura also advocates for integrated assessment and injection visits to optimise outcomes, showcasing successful implementation in his retinal therapy unit in Barcelona.